» Articles » PMID: 34805807

MERS-CoV Confirmation Among 6,873 Suspected Persons and Relevant Epidemiologic and Clinical Features, Saudi Arabia - 2014 to 2019

Overview
Specialty General Medicine
Date 2021 Nov 22
PMID 34805807
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Of the three lethal coronaviruses, in addition to the ongoing pandemic-causing SARS-CoV 2, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) remains in circulation. Information on MERS-CoV has relied on small sample of patients. We updated the epidemiology, laboratory and clinical characteristics, and survival patterns of MERS-CoV retrospectively with the largest sample of followed patients.

Methods: We conducted a retrospective review of line-listed records of non-random, continuously admitted patients who were suspected (6,873) or confirmed with MERS-CoV (501) admitted to one of the four MERS-CoV referral hospitals in Saudi Arabia, 2014-2019.

Findings: Of the 6,873 MERS-CoV suspected persons, the majority were male (56%) and Saudi nationals (83%) and 95% had no known history that increased their risk of exposure to MERS-CoV patients or vectors (95%). More confirmed cases reported history that increased their risk of MERS-CoV infection (41%). Among the suspected, MERS-CoV confirmation (7.4% overall) was independently associated with being male, known transmission link to MERS-CoV patients or vectors, fever, symptoms for 7 days, admission through intensive care unit, and diabetes. Among persons with confirmed MERS-CoV, single symptoms were reported by 20%, 3-symptom combinations (fever, cough and dyspnea) reported by 21% and 2-symptom combinations (fever, cough) reported by 16%. Of the two-thirds (62%) of MERS-CoV confirmed patients who presented with co-morbidity, 32% had 2-"comorbidities (diabetes, hypertension). More than half of the MERS-CoV patents showed abnormal chest X-ray, elevated aspartate aminotransferase, and creatinine kinase. About a quarter of MERS-CoV patients had positive cultures on blood, urine, or respiratory secretions. During an average hospital stay of 18 days (range 11 to 30), 64% developed complications involving liver, lungs, or kidneys. Ventilation requirement (29% of MERS-CoV cases) was independently associated with abnormal chest X-ray, viremia (Ct value <30), elevated creatinine, and prothrombin time. Death (21% overall) was independently associated with older age, dyspnea and abnormal chest X-ray on admission, and low hemoglobulin levels.

Interpretations: With two-thirds of the symptomatic persons developing multiorgan complications MERS-CoV remains the coronavirus with the highest severity (29%) and case fatality rate (21%) among the three lethal coronaviruses. Metabolic abnormalities appear to be an independent risk factor for sustained MERS-CoV transmission. The poorly understood transmission dynamics and non-specific clinical and laboratory features call for high index of suspicion among respiratory disease experts to help early detection of outbreaks. We reiterate the need for case control studies on transmission.

Funding: No special funding to declare.

Citing Articles

A prediction of mutations in infectious viruses using artificial intelligence.

Choi W, Park J, Seong D, Chung D, Hong D Genomics Inform. 2024; 22(1):15.

PMID: 39380083 PMC: 11463117. DOI: 10.1186/s44342-024-00019-y.


Saudi Arabia's Middle East respiratory syndrome Coronavirus (MERS-CoV) outbreak: consequences, reactions, and takeaways.

Salomon I Ann Med Surg (Lond). 2024; 86(8):4668-4674.

PMID: 39118758 PMC: 11305771. DOI: 10.1097/MS9.0000000000002336.


Diabetes Mellitus and Pneumococcal Pneumonia.

Cilloniz C, Torres A Diagnostics (Basel). 2024; 14(8).

PMID: 38667504 PMC: 11049506. DOI: 10.3390/diagnostics14080859.


Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans.

Addetia A, Stewart C, Seo A, Sprouse K, Asiri A, Al-Mozaini M bioRxiv. 2024; .

PMID: 38617298 PMC: 11014493. DOI: 10.1101/2024.03.31.586409.


Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV.

Chao C, Sprouse K, Miranda M, Catanzaro N, Hubbard M, Addetia A bioRxiv. 2024; .

PMID: 38558973 PMC: 10979991. DOI: 10.1101/2024.03.13.584735.


References
1.
Perlman S, Azhar E, Memish Z, Hui D, Zumla A . Confronting the persisting threat of the Middle East respiratory syndrome to global health security. Lancet Infect Dis. 2019; 20(2):158-160. PMC: 7128339. DOI: 10.1016/S1473-3099(19)30347-0. View

2.
Amer H, Alqahtani A, Alaklobi F, Altayeb J, Memish Z . Healthcare worker exposure to Middle East respiratory syndrome coronavirus (MERS-CoV): Revision of screening strategies urgently needed. Int J Infect Dis. 2018; 71:113-116. PMC: 7110437. DOI: 10.1016/j.ijid.2018.04.001. View

3.
Alfaraj S, Al-Tawfiq J, Gautret P, Alenazi M, Asiri A, Memish Z . Evaluation of visual triage for screening of Middle East respiratory syndrome coronavirus patients. New Microbes New Infect. 2018; 26:49-52. PMC: 6138856. DOI: 10.1016/j.nmni.2018.08.008. View

4.
Modjarrad K, Moorthy V, Ben Embarek P, Van Kerkhove M, Kim J, Kieny M . A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. Nat Med. 2016; 22(7):701-5. PMC: 7096003. DOI: 10.1038/nm.4131. View

5.
Memish Z, Zumla A, Assiri A . Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med. 2013; 369(9):884-6. DOI: 10.1056/NEJMc1308698. View